Published in J Neurol Neurosurg Psychiatry on April 01, 1999
Neurologist care in Parkinson disease: a utilization, outcomes, and survival study. Neurology (2011) 2.61
A short scale for the assessment of motor impairments and disabilities in Parkinson's disease: the SPES/SCOPA. J Neurol Neurosurg Psychiatry (2004) 1.20
Discontinuation of ropinirole and pramipexole in patients with Parkinson's disease: clinical practice versus clinical trials. Eur J Clin Pharmacol (2008) 1.05
Pramipexole: new use for an old drug - the potential use of pramipexole in the treatment of restless legs syndrome. Neuropsychiatr Dis Treat (2006) 0.93
Pramipexole in patients with Parkinson's disease and marked drug resistant tremor: a randomised, double blind, placebo controlled multicentre study. J Neurol Neurosurg Psychiatry (2002) 0.90
Treatment of Parkinson's disease in the advanced stage. J Neural Transm (Vienna) (2013) 0.86
Sleep and dreaming are for important matters. Front Psychol (2013) 0.83
Clinical aspects and management of levodopa-induced dyskinesia. Parkinsons Dis (2012) 0.83
Sleep and the processing of emotions. Exp Brain Res (2014) 0.82
Once-daily pramipexole for the treatment of early and advanced idiopathic Parkinson's disease: implications for patients. Neuropsychiatr Dis Treat (2011) 0.80
Effects of a dopamine agonist on the pharmacodynamics of levodopa in Parkinson disease. Arch Neurol (2010) 0.80
The management of orthostatic hypotension in Parkinson's disease. Front Neurol (2013) 0.80
Update on the use of pramipexole in the treatment of Parkinson's disease. Neuropsychiatr Dis Treat (2008) 0.79
Non-Ergot Dopamine Agonists Do Not Increase the Risk of Heart Failure in Parkinson's Disease Patients: A Meta-Analysis of Randomized Controlled Trials. J Clin Med Res (2016) 0.78
The efficacy and safety of pramipexole ER versus IR in Chinese patients with Parkinson's disease: a randomized, double-blind, double-dummy, parallel-group study. Transl Neurodegener (2014) 0.78
Continuous dopaminergic stimulation (CDS)-based treatment in Parkinson's disease patients with motor complications: a systematic review and meta-analysis. Sci Rep (2014) 0.76
Dyskinesias and treatment with pramipexole in patients with Parkinson's disease. Parkinsons Dis (2012) 0.75
Efficacy of antidepressive medication for depression in Parkinson disease: a network meta-analysis. Medicine (Baltimore) (2017) 0.75
Pramipexole and its extended release formulation for Parkinson's disease. J Cent Nerv Syst Dis (2011) 0.75
Nonergot dopamine-receptor agonists for treating Parkinson's disease - a network meta-analysis. Neuropsychiatr Dis Treat (2014) 0.75
Side effects of a dopamine agonist therapy for Parkinson's disease: a mini-review of clinical pharmacology. Yale J Biol Med (2016) 0.75
Comparison for Efficacy and Tolerability among Ten Drugs for Treatment of Parkinson's Disease: A Network Meta-Analysis. Sci Rep (2017) 0.75
Functional Magnetic Resonance Imaging Neurofeedback-guided Motor Imagery Training and Motor Training for Parkinson's Disease: Randomized Trial. Front Behav Neurosci (2016) 0.75
Parkinsonism: onset, progression and mortality. Neurology (1967) 36.06
The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry (1988) 14.72
Retroperitoneal fibrosis and treatment of Parkinson's disease with high doses of bromocriptine. Clin Neuropharmacol (1986) 1.25
Pramipexole binding and activation of cloned and expressed dopamine D2, D3 and D4 receptors. Eur J Pharmacol (1995) 1.21
Clinical evaluation of pramipexole in advanced Parkinson's disease: results of a double-blind, placebo-controlled, parallel-group study. Neurology (1997) 1.16
Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson's disease. International Pramipexole-Bromocriptine Study Group. Neurology (1997) 1.13
Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease. The Pramipexole Study Group. Neurology (1997) 1.08
Pramipexole in patients with early Parkinson's disease. Clin Neuropharmacol (1995) 1.04
Steady-state pharmacokinetic properties of pramipexole in healthy volunteers. J Clin Pharmacol (1997) 0.97
In vivo comparisons of the effects of quinpirole and the putative presynaptic dopaminergic agonists B-HT 920 and SND 919 on striatal dopamine and acetylcholine release. J Pharmacol Exp Ther (1993) 0.87
Dopamine receptor agonist potencies for inhibition of cell firing correlate with dopamine D3 receptor binding affinities. Eur J Pharmacol (1995) 0.87
The use of pramipexole, a novel dopamine (DA) agonist, in advanced Parkinson's disease. J Neural Transm Suppl (1995) 0.85
Bromocriptine and pleuropulmonary disease. Arch Intern Med (1989) 0.82
Erythromelalgia-like eruption in parkinsonian patients treated with bromocriptine. Neurology (1981) 0.82
Neurostimulation for Parkinson's disease with early motor complications. N Engl J Med (2013) 6.37
The role of radiotracer imaging in Parkinson disease. Neurology (2005) 3.02
Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: a combined retrograde tracing and immunocytochemical study in the rat. Neuroscience (1994) 2.40
Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer's disease. J Neurol Neurosurg Psychiatry (2004) 2.12
Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: the [123I]-FP-CIT study group. Mov Disord (2000) 2.10
Possible environmental, occupational, and other etiologic factors for Parkinson's disease: a case-control study in Germany. Neurology (1996) 2.01
Intravenous levetiracetam in the treatment of benzodiazepine refractory status epilepticus. J Neurol Neurosurg Psychiatry (2007) 1.80
Association of an interleukin 1 alpha polymorphism with Alzheimer's disease. Neurology (2000) 1.76
Static mechanical hyperalgesia without dynamic tactile allodynia in patients with restless legs syndrome. Brain (2004) 1.75
DTI reveals hypothalamic and brainstem white matter lesions in patients with idiopathic narcolepsy. Sleep Med (2012) 1.68
Diet and Parkinson's disease. II: A possible role for the past intake of specific nutrients. Results from a self-administered food-frequency questionnaire in a case-control study. Neurology (1996) 1.68
The combination of hypointense and hyperintense signal changes on T2-weighted magnetic resonance imaging sequences: a specific marker of multiple system atrophy? Arch Neurol (1999) 1.66
Five subtypes of type A gamma-aminobutyric acid receptors identified in neurons by double and triple immunofluorescence staining with subunit-specific antibodies. Proc Natl Acad Sci U S A (1992) 1.55
A point mutation in PTPRC is associated with the development of multiple sclerosis. Nat Genet (2000) 1.54
Effective cabergoline treatment in idiopathic restless legs syndrome. Neurology (2004) 1.51
Perineuronal nets provide a polyanionic, glia-associated form of microenvironment around certain neurons in many parts of the rat brain. Glia (1993) 1.49
Incidence of status epilepticus in adults in Germany: a prospective, population-based study. Epilepsia (2001) 1.49
CNS involvement in hereditary neuropathy with pressure palsies (HNPP). Neurology (2006) 1.44
Coexistence of galanin-like immunoreactivity with catecholamines, 5-hydroxytryptamine, GABA and neuropeptides in the rat CNS. J Neurosci (1986) 1.43
Production of a specific antiserum to rat brain glutamic acid decarboxylase by injection of an antigen-antibody complex. Neuroscience (1981) 1.40
Activation mapping in essential tremor with functional magnetic resonance imaging. Ann Neurol (1997) 1.30
Patterns of cerebrospinal fluid pathology correlate with disease progression in multiple sclerosis. Brain (2001) 1.30
Men and women are different: diffusion tensor imaging reveals sexual dimorphism in the microstructure of the thalamus, corpus callosum and cingulum. Neuroimage (2010) 1.24
Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson's disease. Eur J Neurol (2013) 1.24
Cerebral generators involved in the pathogenesis of the restless legs syndrome. Ann Neurol (1997) 1.23
Prefrontal direct current stimulation modulates resting EEG and event-related potentials in healthy subjects: a standardized low resolution tomography (sLORETA) study. Neuroimage (2010) 1.22
Starnberg trial on epidemiology of Parkinsonism and hypertension in the elderly. Prevalence of Parkinson's disease and related disorders assessed by a door-to-door survey of inhabitants older than 65 years. Arch Neurol (1995) 1.21
Bilateral caudate and putamen grafts of embryonic mesencephalic tissue treated with lazaroids in Parkinson's disease. Brain (2000) 1.18
Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients. J Neurol Neurosurg Psychiatry (1997) 1.17
Cell-specific immuno-probes for the brain of normal and mutant Drosophila melanogaster. I. Wildtype visual system. Cell Tissue Res (1988) 1.16
Motor cortex excitability in focal epilepsies not including the primary motor area--a TMS study. Brain (2005) 1.12
In vivo imaging of region and cell type specific neocortical neurodegeneration in Alzheimer's disease. Perspectives of MRI derived corpus callosum measurement for mapping disease progression and effects of therapy. Evidence from studies with MRI, EEG and PET. J Neural Transm (Vienna) (2002) 1.07
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in non-human primates is antagonized by pretreatment with nimodipine at the nigral, but not at the striatal level. Brain Res (1996) 1.06
Central GABAergic innervation of neurointermediate pituitary lobe: biochemical and immunocytochemical study in the rat. Proc Natl Acad Sci U S A (1982) 1.05
A randomized controlled study of pergolide in patients with restless legs syndrome. Neurology (1999) 1.05
T2 relaxation time in patients with Parkinson's disease. Neurology (1993) 1.05
Immunocytochemical localization of glutamate decarboxylase in rat cerebellum with a new antiserum. Neuroscience (1981) 1.04
Two-color immunohistochemistry for dopamine and GABA neurons in rat substantia nigra and zona incerta. Brain Res Bull (1983) 1.03
Health-related quality of life and healthcare utilisation in patients with Parkinson's disease: impact of motor fluctuations and dyskinesias. Pharmacoeconomics (2001) 1.03
Atypical parkinsonism in Guadeloupe: a common risk factor for two closely related phenotypes? Brain (2007) 1.02
The economic impact of Parkinson's disease. An estimation based on a 3-month prospective analysis. Pharmacoeconomics (1998) 1.02
Low-frequency rTMS of the vertex in the prophylactic treatment of migraine. Cephalalgia (2010) 1.01
Topiramate, nutrition and weight change: a prospective study. J Neurol Neurosurg Psychiatry (2007) 1.00
Late-onset myoclonic epilepsy in Down's syndrome (LOMEDS). Seizure (2002) 0.98
Long-term changes of striatal dopamine D2 receptors in patients with Parkinson's disease: a study with positron emission tomography and [11C]raclopride. Mov Disord (1997) 0.97
Single-trial coupling of the gamma-band response and the corresponding BOLD signal. Neuroimage (2009) 0.97
[11C]raclopride and positron emission tomography in previously untreated patients with Parkinson's disease: Influence of L-dopa and lisuride therapy on striatal dopamine D2-receptors. Neurology (1994) 0.97
Olfactory dysfunction in patients with narcolepsy with and without REM sleep behaviour disorder. Brain (2007) 0.97
Clinical and biochemical findings in uremic patients with and without restless legs syndrome. Am J Kidney Dis (1998) 0.97
Longitudinal study of the socioeconomic burden of Parkinson's disease in Germany. Eur J Neurol (2010) 0.97
Evidence for estrogen-receptive GABAergic neurons in the preoptic/anterior hypothalamic area of the rat brain. Neuroendocrinology (1986) 0.96
Effects of transcranial direct current stimulation on pain perception and working memory. Eur J Pain (2012) 0.96
Clinical symptoms and possible anticipation in a large kindred of familial restless legs syndrome. Mov Disord (1996) 0.96
Development and evaluation of the Parkinson Psychosis Questionnaire A screening-instrument for the early diagnosis of drug-induced psychosis in Parkinson's disease. J Neurol (2005) 0.96
Pharmacotherapy of Parkinson's disease in Germany. J Neurol (2005) 0.96
Pregabalin-induced generalized myoclonic status epilepticus in patients with chronic pain. Epilepsy Behav (2007) 0.95
Pretreatment with nimodipine prevents MPTP-induced neurotoxicity at the nigral, but not at the striatal level in mice. Neuroreport (1995) 0.95
Coexistence of glutamic acid decarboxylase- and somatostatin-like immunoreactivity in neurons of the feline nucleus reticularis thalami. J Neurosci (1983) 0.95
Relationship between clinical features of Parkinson's disease and presynaptic dopamine transporter binding assessed with [123I]IPT and single-photon emission tomography. Eur J Nucl Med (1997) 0.95
Pain sensitivity and descending inhibition of pain in Parkinson's disease. J Neurol Neurosurg Psychiatry (2008) 0.94
Glutamic acid decarboxylase immunoreactivity is present in perikarya of neurons in nucleus tractus solitarius of rat. Brain Res (1984) 0.94
Diet and Parkinson's disease. I: A possible role for the past intake of specific foods and food groups. Results from a self-administered food-frequency questionnaire in a case-control study. Neurology (1996) 0.94
Immunocytochemical studies of GABAergic neurons in rat basal ganglia and their relations to other neuronal systems. Neurosci Lett (1984) 0.93
Time course of chemokines in the cerebrospinal fluid and serum during herpes simplex type 1 encephalitis. J Neurol Sci (1998) 0.93
The neural basis of the P300 potential. Focus on the time-course of the underlying cortical generators. Eur Arch Psychiatry Clin Neurosci (2004) 0.93
Dose standardization of botulinum toxin. Mov Disord (1998) 0.92
Candidate gene studies in focal dystonia. Neurology (2003) 0.92
Rapid identification of local T cell expansion in inflammatory organ diseases by flow cytometric T cell receptor Vbeta analysis. J Immunol Methods (2000) 0.91
Transcranial direct current stimulation in treatment resistant depression: a randomized double-blind, placebo-controlled study. Brain Stimul (2011) 0.91
Pramipexole in patients with Parkinson's disease and marked drug resistant tremor: a randomised, double blind, placebo controlled multicentre study. J Neurol Neurosurg Psychiatry (2002) 0.90
Immunocytochemical localization of GABA neurons and dopamine neurons in the rat main and accessory olfactory bulbs. Neurosci Lett (1984) 0.89
Striato-nigral dynorphin and substance P pathways in the rat. I. Biochemical and immunohistochemical studies. Exp Brain Res (1986) 0.89
123I-iodobenzamide-SPECT predicts dopaminergic responsiveness in patients with de novo parkinsonism. Neurology (1992) 0.89
Increased numbers of GABAergic neurons occur in the inferior colliculus of an audiogenic model of genetic epilepsy. Brain Res (1985) 0.89
Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline. J Neural Transm (Vienna) (2001) 0.89
Sleep disturbances in Parkinson's disease patients and spouses. J Am Geriatr Soc (1997) 0.88
A controlled study of additional sr-L-dopa in L-dopa-responsive restless legs syndrome with late-night symptoms. Neurology (1999) 0.88
Quantitative [(123)I]FP-CIT pinhole SPECT imaging predicts striatal dopamine levels, but not number of nigral neurons in different mouse models of Parkinson's disease. Neuroimage (2007) 0.88
Signal changes on MRI and increases in reactive microgliosis, astrogliosis, and iron in the putamen of two patients with multiple system atrophy. J Neurol Neurosurg Psychiatry (1996) 0.88
Comparison of 123I-IBZM SPECT and 11C-raclopride PET findings in patients with parkinsonism. Nucl Med Commun (1994) 0.88
Opioid peptide-like immunoreactivity localized in GABAErgic neurons of rat neostriatum and central amygdaloid nucleus. Life Sci (1983) 0.88
Apomorphine test for dopaminergic responsiveness in patients with previously untreated Parkinson's disease. Arch Neurol (1992) 0.88
Safety and tolerability of adjunctive tolcapone treatment in patients with early Parkinson's disease. J Neurol Neurosurg Psychiatry (2006) 0.88
Comparison of cysteine sulphinic acid decarboxylase isoenzymes and glutamic acid decarboxylase in rat liver and brain. Neuroscience (1981) 0.87
Effects of nicotine on hydroxyl free radical formation in vitro and on MPTP-induced neurotoxicity in vivo. Naunyn Schmiedebergs Arch Pharmacol (1998) 0.87
Long-term effects of pergolide in the treatment of restless legs syndrome. Neurology (2001) 0.87
CD45 isoform expression in autoimmune myasthenia gravis. Autoimmunity (2003) 0.87
Immunocytochemical demonstration of the GABA-ergic neurons in rat globus pallidus and nucleus entopeduncularis and their GABA-ergic innervation. Adv Neurol (1984) 0.86
Predominant affection of the blue cone pathway in Parkinson's disease. Brain (1995) 0.86
Costs of drug treatment in Parkinson's disease. Mov Disord (1998) 0.86
Salicylate protects against MPTP-induced impairments in dopaminergic neurotransmission at the striatal and nigral level in mice. Naunyn Schmiedebergs Arch Pharmacol (1999) 0.86
Evaluation of healthcare utilization and health status of patients with Parkinson's disease treated with deep brain stimulation of the subthalamic nucleus. J Neurol (2002) 0.86
Marked reduction of striatal dopamine D2 receptors as detected by 123IBZM-SPECT in a Wilson's disease patient with generalized dystonia. Mov Disord (1992) 0.86
Age effects on the P300 potential and the corresponding fMRI BOLD-signal. Neuroimage (2012) 0.86
Parkinson's disease--medical education and psychosocial aspects. Patient Educ Couns (1995) 0.86